Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Comfort Systems USA Inc (FIX) Price & Performance

ADMA Biologics IncTrade
Comfort Systems USA IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Comfort Systems USA Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Comfort Systems USA Inc trades at $1,677.95 (market cap $58.94B). The key difference: Comfort Systems USA Inc is far larger — about 27× ADMA Biologics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAFIX
Market Cap
$2.18B$58.94B
Sector
HealthTechnology
52-Week High
$20.38$2.07K
52-Week Low
$7.60$680.86
Enterprise Value
$2.25B$57.42B
Dividend Yield
0.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Comfort Systems USA Inc

FIX trades at $1,694.55, down 1.11% today, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating estimates with EPS of $12.53 versus $10.45 expected, driven by robust data center demand. Revenue grew to $11.2B in 2026, with net profit margin expanding to 12.77%. Analyst consensus is bullish with a $2,170 price target, though valuation multiples like P/E of 41.22 appear elevated.

Outlook remains positive given record backlog and AI-driven demand, but risks include high execution demands and premium valuation. The stock offers growth exposure to the construction and data center sectors, supported by institutional interest and consistent dividend payments, though investors should monitor capacity constraints and competitive pressures.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Comfort Systems USA Inc

Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.

Read more on FIX